London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’

AI Summary

London-based startup Poolbeg Pharma is set to trial an oral drug called POLB 001 at six NHS hospitals aiming to prevent cytokine release syndrome, a dangerous side effect of cancer immunotherapy. The company is also developing a GLP-1 weight loss pill, targeting improvements in cancer treatment safety and metabolic health.

Poolbeg Pharma to test the treatment in NHS hospitals and says it is also developing a GLP-1 weight loss pill A London-based startup is about to trial a drug at six NHS hospitals that could stop people on cancer immunotherapy getting a life-threatening side-effect. Poolbeg Pharma said its oral drug POLB 001 could make treatment for blood cancer safer by preventing cytokine release syndrome (CRS), when the immune system goes into overdrive and attacks the body, leading to organ damage. Continue reading...